New drug duo aims to shrink esophageal tumors before surgery

NCT ID NCT07627347

Recruiting now Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 06, 2026 · Last updated Jun 13, 2026 · Updated 2 times

Summary

This study tests whether giving two drugs (anlotinib and bemocizumab) before surgery can improve outcomes for people with a type of esophageal cancer. About 25 adults with stage II-IIIB esophageal squamous cell carcinoma will receive the combination, then have surgery. The goal is to see if the drugs help remove all cancer cells and reduce the chance of the cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanfang Hospital, Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510515, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ESCC

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA